EWTX
Edgewise Therapeutics (EWTX) soared more than 20% on Monday after French drugmaker Servier unveiled a...
Article Summary
HOLD- Edgewise Therapeutics (EWTX) soared more than 20% on Monday after French drugmaker Servier unveiled a multibillion-dollar deal to acquire Edgewise Therapeutics's muscular dystrophy business, including programs targeting Becker and Duchenne muscular dystrophies, with the acquisition expected to close in the third quarter of 2026.
- The acquisition includes Edgewise's muscular Dystrophy operations and its lead drug candidate, Sevasemten, currently being evaluated in pivotal trials for Becker muscular dystrand and DMD, with data showing patients maintained stable physical function for up to 3.5 years, compared with the decline typically seen in the disease, and demonstrated a favorable cardiac safety profile over 12 months.
- Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $ 1.1 billion tied to regulatory and commercial milestones, and the transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support continued development for people living with BMD or DMD.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | -1.5% | 25% | 0.0 ptsNegative (-1.5%) - Declining expectations |
| Target Price Upside ? | 12.0% | 20% | 50.0 ptsMeets Minimum (12.0%) - Target: $43.67 vs Current: $38.99 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -2.4% | 15% | 20.0 ptsBarely a Dip (-2.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About EWTX
- Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
- Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
- The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction.
- In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
- The company was incorporated in 2017 and is headquartered in Boulder, Colorado.